Stapleless vs Stapled Gastric Bypass vs Hypocaloric Diet: a Three-Arm Randomized Controlled Trial of Body Mass Evolution with Secondary Outcomes for Telomere Length and Metabolic Syndrome Changes

• Published in: Obesity surgery 2021-07, Vol.31 (7), p.3165-3176
• Main Authors: Ospanov, Oral, Akilzhanova, Ainur, Buchwald, J. N., Fursov, Alexandr, Bekmurzinova, Farida, Rakhimova, Saule, Yeleuov, Galymzhan, Kozhamkulov, Ulan, Abdina, Zhanar, Fursov, Roman, Jumayeva, Lyudmila
• Format: Article
• Language: English
• Subjects: Clinical trials; Gastrointestinal surgery; Laparoscopy; Life expectancy; Medicine; Medicine & Public Health; Metabolic syndrome; Original Contributions; Surgery; Weight control
• ISSN: 0960-8923; 1708-0428
• DOI: 10.1007/s11695-021-05454-2

Background Obesity and metabolic syndrome (MetS) reduce life expectancy and are challenging to resolve. This randomized controlled trial (RCT) of patients with obesity and MetS undergoing surgical vs nonsurgical treatment compared changes in BMI, and secondarily, telomere length (as a biomarker of life expectancy) and changes in MetS components (insulin resistance, dyslipidemia, hypertension). Methods Study design was a single-center, prospective, three-arm RCT. Group 1 patients underwent novel unstapled laparoscopic one anastomosis gastric bypass with an obstructive stapleless pouch and anastomosis (LOAGB-OSPAN); Group 2, stapled laparoscopic mini-gastric bypass-one anastomosis gastric bypass (LMGB-OAGB); and Group 3, nonsurgical weight loss therapy via a hypocaloric diet with energy restriction (HDER). The primary outcome measure was change in BMI; secondary outcome measures included change in leukocyte telomere length and other MetS components. Results Of 96 participants screened, 60 were randomly allocated to 3 groups: LOAGB-OSPAN group ( n = 20), LMGB-OAGB group ( n = 20), and HDER group ( n = 20). At post-treatment month 12, respective BMI changes: BMI −12.13 (−8.34, −15.93); −16.04 (−11.7, 20.37); −2,76 (−3.84, −9.36) ( p < 0.01). The two surgical groups experienced significant change in telomere length: LOAGB-OSPAN 2.02 (1.61, 2.41), p = 0.001; LMGB-OAGB 2.07 (1.72, 2.43), p = 0.001; and HDER 0.28 (0.22, 0.78), p = 0.26. The surgical groups were also more effective in treating MetS components. There were no deaths. Adverse events: LOAGB-OSPAN ( n = 2) (Clavien-Dindo grade II); LMGB-OAGB ( n = 8) (grade I ( n = 6) and grade II ( n = 2). Conclusions Compared with hypocaloric diet therapy, both bariatric procedures resulted in greater BMI loss, and secondarily, a significant increase in telomere length, and greater MetS resolution. Trial registration ClinicalTrials.gov , NCT03667469, registered on 11 September 2018. Graphical abstract